AngioDynamics Affirms FY2027 Adj EPS Guidance of $(0.29)-$(0.24) vs $(0.27) Est; Affirms FY2027 Sales Guidance of $336.000M-$341.000M vs $337.400M Est

Benzinga Newsdesk www.benzinga.com Negative 48.3%

Neg 48.3% Neu 0% Pos 0%

AngioDynamics (NASDAQ:ANGO) affirms FY2027 Adj EPS guidance from $(0.29)-$(0.24) to $(0.29)-$(0.24) vs $(0.27) analyst estimate. Affirms FY2027 sales outlook from $336.000 million-$341.000 million to $336.000 million-$341.000 million vs $337.400 million estimate.